Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of ferroportin disease and SLC40A1-related hemochromatosis - Results from the EASL non-HFE registry.

Journal of hepatology·2026
Same author

Genome-wide association for sarcoidosis identifies novel risk loci and genetic heritability in African and European ancestries: a meta-analysis from the Finngen, Million Veteran Program, UK Biobank, and Biobank Japan datasets.

Orphanet journal of rare diseases·2025
Same author

Alterations in iron status predict cardiac response to blood transfusion in β-thalassemia major.

Scientific reports·2025
Same author

Lipidic nanomedicines enhance Hinokitiol activity on human primary macrophages from Ferroportin disease patients.

International journal of pharmaceutics·2025
Same author

Porphyrias: Pathophysiology and clinical management recommendations for hepatologists.

Hepatology communications·2025
Same author

Diagnosis and Management of Non-HFE Hemochromatosis, Ferroportin Disease, and Rare Hereditary Iron-Loading Disorders.

Advances in experimental medicine and biology·2025
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

Non-HFE hepatic iron overload.

Antonello Pietrangelo1, Angela Caleffi, Elena Corradini

  • 1Division of Internal Medicine 2 and Center for Hemochromatosis, "Mario Coppo" Liver Research Center, University Hospital of Modena, Modena, Italy. antonello.pietrangelo@unimore.it

Seminars in Liver Disease
|September 9, 2011
PubMed
Summary
This summary is machine-generated.

Non-HFE hemochromatosis syndromes involve genetic mutations affecting hepcidin, leading to liver iron overload. Ferroportin disease, a common form, presents milder symptoms and affects diverse populations.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Related Experiment Videos

Last Updated: May 29, 2026

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Area of Science:

  • Hepatology
  • Medical Genetics
  • Biochemistry

Background:

  • Pathologic iron accumulation in the liver can stem from various clinical conditions, including hereditary and non-hereditary factors.
  • Non-HFE hemochromatosis syndromes are a group of hereditary iron-loading disorders sharing a common pathogenic basis (impaired hepcidin) with HFE-hemochromatosis but caused by mutations in different genes.
  • These syndromes, unlike HFE-hemochromatosis, are not limited to Caucasian populations and include mutations in genes like TFR2, HAMP, HJV, and FPN.

Purpose of the Study:

  • To review and categorize the diverse causes of hepatic iron accumulation, focusing on hereditary iron-loading disorders.
  • To differentiate non-HFE hemochromatosis syndromes from classic HFE-hemochromatosis, highlighting genetic and clinical distinctions.
  • To discuss ferroportin disease as a prominent non-HFE disorder and briefly mention other rarer genetic and acquired causes of liver iron overload.

Main Methods:

  • Literature review and synthesis of existing clinical and genetic data on hepatic iron overload disorders.
  • Comparative analysis of HFE-hemochromatosis and non-HFE hereditary iron-loading syndromes based on genetic etiology, pathophysiology, and clinical presentation.
  • Classification of iron-loading disorders, including hereditary (non-HFE) and non-hereditary conditions.

Main Results:

  • Non-HFE hemochromatosis syndromes are caused by mutations in genes other than HFE, affecting hepcidin synthesis or activity, and present with liver iron accumulation.
  • Ferroportin disease, an autosomal dominant disorder caused by FPN mutations, is the most common non-HFE hereditary iron-loading disorder, characterized by Kupffer cell iron accumulation and milder symptoms.
  • Other rarer genetic disorders (e.g., atransferrinemia, aceruloplasminemia) and acquired conditions (e.g., chronic liver diseases) can also lead to hepatic iron accumulation, often with distinct clinical manifestations.

Conclusions:

  • Understanding the genetic heterogeneity of hereditary iron-loading disorders beyond HFE is crucial for accurate diagnosis and management.
  • Ferroportin disease represents a significant subgroup of hereditary iron overload with distinct genetic and clinical features.
  • Hepatic iron accumulation can result from a spectrum of genetic and non-genetic factors, necessitating a comprehensive diagnostic approach.